Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials

求助中 10 由达姆发布于 2026/2/24 14:50:49

DOI:10.1016/s2468-1253(25)00267-5
作者：Jian Li, Zhenghang Wang, Jing Huang, Yi Ba, Baoshan Cao, Suxia Luo, Wenhua Li, Chunmei Bai, Zhengbo Song, Jianping Xiong, Liangjun Zhu, Guangyu An, Yanqiao Zhang, Zhihua Li, Yongsheng Li, Yanhong Gu,
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：BackgroundKRASG12C mutations are present in around 4% of patients with colorectal cancer and are associated with lower treatment response rates and overall survival. EGFR signalling has been

应助信息

等您来应助

上传文件

17小时前

华山论剑

33e02e5a114d11f1aaae34735aa3bc31.pdf 已驳回

17小时前

Book学术机器人

2026/2/24 14:50:50 未找到该文献，机器人已退出，请等待人工下载

2026/2/24 14:50:50 Book学术AI机器人收到请求，开始寻找文献

2026/2/24 14:50:50 已向机器人发送请求

17小时前

达姆发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库Adaptive Genomic Features of Raoultella ornithinolytica LAM1 from the Geothermal Site of Los Azufres Reveal Potential for Heavy-Metal Bioremediation.